As these therapies become more widespread, physicians are tasked with balancing profound weight loss against the potential for sarcopenia and long-term frailty
Early responders who lost at least 15 percent of their body weight by week 24 went on to achieve an incredible 27.7 percent mean weight loss by week 72 (Source: STEP UP Trial, Dicker et al., ECO Abstract 2026)
After one year, 42% of adults on Zepbound and 50% of adults on Zepbound with PAP therapy experienced remission or mild, non-symptomatic OSA, compared to 16% and 14% on placebo, respectively
This indicates that patients may still experience the appetite regulation benefits of GLP-1s, even at lower doses, and the effects may be more gradual and gentler, which could be beneficial for long-term adherence
Keep a water bottle within arm reach at all times
Supplying high-purity, research-grade compounds intended strictly for laboratory and analytical purposes